Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 5.5%

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares fell 5.5% on Wednesday . The company traded as low as $8.06 and last traded at $8.11. 1,064,603 shares traded hands during trading, a decline of 83% from the average session volume of 6,098,068 shares. The stock had previously closed at $8.58.

Analyst Ratings Changes

Several research firms have commented on RXRX. Needham & Company LLC reiterated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research note on Tuesday, June 25th. KeyCorp decreased their price target on Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th.

Recursion Pharmaceuticals Price Performance

The firm has a market cap of $1.86 billion, a PE ratio of -5.01 and a beta of 0.83. The business’s fifty day moving average is $8.60 and its 200-day moving average is $9.66.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.04. Recursion Pharmaceuticals had a negative net margin of 765.90% and a negative return on equity of 79.96%. The company had revenue of $13.80 million for the quarter, compared to analysts’ expectations of $11.10 million. During the same quarter in the previous year, the firm posted ($0.34) EPS. Recursion Pharmaceuticals’s revenue was up 14.0% on a year-over-year basis. Analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.56 EPS for the current year.

Insider Activity

In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $7.95, for a total value of $91,003.65. Following the completion of the sale, the director now owns 7,218,414 shares of the company’s stock, valued at approximately $57,386,391.30. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Recursion Pharmaceuticals news, CEO Christopher Gibson sold 50,000 shares of the stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $7.48, for a total transaction of $374,000.00. Following the sale, the chief executive officer now owns 758,738 shares in the company, valued at $5,675,360.24. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $7.95, for a total value of $91,003.65. Following the completion of the transaction, the director now owns 7,218,414 shares of the company’s stock, valued at $57,386,391.30. The disclosure for this sale can be found here. Insiders have sold 249,235 shares of company stock valued at $2,009,063 in the last 90 days. Insiders own 15.75% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in RXRX. ARK Investment Management LLC lifted its holdings in shares of Recursion Pharmaceuticals by 200.4% in the fourth quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock worth $203,651,000 after buying an additional 13,777,689 shares in the last quarter. Mubadala Investment Co PJSC purchased a new stake in Recursion Pharmaceuticals in the 4th quarter worth approximately $128,041,000. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in Recursion Pharmaceuticals by 161.2% in the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 9,203,780 shares of the company’s stock valued at $90,749,000 after purchasing an additional 5,680,656 shares during the period. Nikko Asset Management Americas Inc. grew its position in shares of Recursion Pharmaceuticals by 161.2% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock valued at $90,565,000 after purchasing an additional 5,680,656 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Recursion Pharmaceuticals by 37.7% in the third quarter. Vanguard Group Inc. now owns 15,506,834 shares of the company’s stock worth $118,627,000 after purchasing an additional 4,247,002 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.